Figure 3.
![Main outcome results. (A) OS (n = 149): median, not reached; 3-year rate, 71% (95% confidence interval [CI], 63-79). (B) EFS (n = 149): median, not reached; 3-year rate, 59% (95% CI, 51-68). (C) DFS (n = 132): median, not reached; 3-year rate, 65% (95% CI, 56-74). (D) The 3-year OS of CR patients receiving blinatumomab 1 (n = 122) was 82% (95% CI, 74-90). (E) The 3-year DFS of CR patients receiving blinatumomab 1 (n = 122) was 68% [95% CI, 60-78]). (F) The 3-year OS according to TP3 MRD status after blinatumomab was as follows: MRD− (n = 102), 81% (95% CI, 73-90); MRD+ (n = 8), 80% (95% CI, 52-100); MRD unknown (n = 12), 88% (95% CI, 76-100); P = .66.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/145/21/10.1182_blood.2024027500/3/blood_bld-2024-027500-gr3.jpeg?Expires=1751702183&Signature=GWAjiEd4QbcWmj1k88LTUj771OXg0RL9oNZj3VViMSRKTniMH6hX8vvJ1G~v-HZeqjhiF8tVIUZvwibKKeLlpY8JYOCHQougvyHriFsLB9T73WW5azBdhjLX0kj95NBkisg8UsAPkaz8BZi2UIf0tS079awo4GchRISiXyvceynmsVsMvHlcyMklH83lHlo-gipK-0AW99QGcy2dOrmHMkODksvcStoTZqPaBDKcj1u50AcYxyARQ-JF0WgxDA306usg8NZdUwQy9UyXQazstyhLBMtNQEMaBB4glVyaW9~XpbORa9HytzGWBRzvGh39rlnhTLKanZI00iqLtkxY8g__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Main outcome results. (A) OS (n = 149): median, not reached; 3-year rate, 71% (95% confidence interval [CI], 63-79). (B) EFS (n = 149): median, not reached; 3-year rate, 59% (95% CI, 51-68). (C) DFS (n = 132): median, not reached; 3-year rate, 65% (95% CI, 56-74). (D) The 3-year OS of CR patients receiving blinatumomab 1 (n = 122) was 82% (95% CI, 74-90). (E) The 3-year DFS of CR patients receiving blinatumomab 1 (n = 122) was 68% [95% CI, 60-78]). (F) The 3-year OS according to TP3 MRD status after blinatumomab was as follows: MRD− (n = 102), 81% (95% CI, 73-90); MRD+ (n = 8), 80% (95% CI, 52-100); MRD unknown (n = 12), 88% (95% CI, 76-100); P = .66.
